Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Johnson and Johnson
Colorcon
Moodys

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,145,684

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,145,684
Title: Surface modified drug nanoparticles
Abstract:Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions containing the particles. Pharmaceutical compositions containing the particles exhibit unexpected bioavailability and are useful in methods of treating mammals.
Inventor(s): Liversidge; Gary G. (West Chester, PA), Cundy; Kenneth C. (Pottstown, PA), Bishop; John F. (Rochester, NY), Czekai; David A. (Honeoye Falls, NY)
Assignee: Sterling Drug Inc. (New York, NY)
Application Number:07/647,105
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,145,684
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,145,684

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 5,145,684

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 150297   Start Trial
Austria 184202   Start Trial
Austria 190835   Start Trial
Austria 195416   Start Trial
Australia 1014592   Start Trial
Australia 1014792   Start Trial
Australia 4156093   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKesson
Harvard Business School
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.